For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and prompting the company to spend billions of dollars on new factories to keep up with demand.

Eli Lilly and Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling addictive behaviors like alcohol abuse, smoking and drug addiction, Chief Executive Officer Dave Ricks said.